Shanghai Pharma cuts pricing on $500m refi
Shanghai Pharmaceuticals Holding Co has managed to slice the margin and fees on a $500m comeback to the loan market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: